Leerink analyst Christopher Liu lowered the firm’s price target on Relay Therapeutics (RLAY) to $18 from $19 and keeps an Outperform rating on the shares after the company announced that lirafugratinib will be out licensed to Elevar Therapeutics. Recall, the company had previously announced its decision to seek a global commercial partner for lirafugratinib during a company event in September 2024. Overall, Leerink thinks this decision is a prudent use of resources given the relatively small size of FGFR2+ populations.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RLAY:
- Relay Therapeutics price target lowered to $16 from $20 at H.C. Wainwright
- Relay Therapeutics, Elevar Therapeutics enter licensing agreement
- Relay Therapeutics price target raised to $20 from $19 at H.C. Wainwright
- Relay Therapeutics Reports Q3 2024 Results and Advances
- Relay Therapeutics reports Q3 EPS (63c), consensus (77c)